Arcturus Therapeutics Announces Redomiciliation to the United States as a Delaware Corporation

Home/Client News/Arcturus Therapeutics Announces Redomiciliation to the United States as a Delaware Corporation

Arcturus Therapeutics Announces Redomiciliation to the United States as a Delaware Corporation

SAN DIEGO, June 13, 2019 (GLOBE NEWSWIRE) — Arcturus Therapeutics Holdings Inc. (ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it has obtained approval from the Israeli Court to complete the redomiciliation process to the United States as a Delaware corporation, which was approved by the Company’s shareholders on May 17, 2019 (99.7% votes in favor).

By | 2019-06-13T15:20:16+00:00 June 13th, 2019|Client News|Comments Off on Arcturus Therapeutics Announces Redomiciliation to the United States as a Delaware Corporation